A service of the U.S.

National Library of Medicine

My NCBI
and the National Institutes of Health
[Sign In] [Register]

All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books
Advanced Search
Search PubMed for Go
Clear
Limits Preview/Index History Clipboard Details

Display AbstractPlus Show 20 Sort By Send to

All: 1 Review: 0

1: Int J Vitam Nutr Res Suppl. 1982;23:103-13. Links

Prolongation of survival times of terminal cancer patients by administration of large doses of Related Articles
ascorbate.
Supplemental ascorbate in the supportive treatment of cancer: reevaluation of
[P roc Natl Acad Sci U SA. 1978]
prolongation of survival times in terminal human cancer.
Murata A, Morishige F, Yamaguchi H.
Supplemental ascorbate in the supportive treatment of cancer: Prolongation of
survival times in terminal human cancer. [P roc Natl Acad Sci U SA. 1976]
Clinical trials administering supplemental ascorbate to terminal cancer patients were conducted at two
hospitals in Japan. During the period 1973-1977 there were 99 patients with terminal cancer at the Fukuoka Innovation vs. quality control: an 'unpublishable' clinical trial of supplemental
Torikai Hospital. The average times of survival after the date of designation as terminal were 43 days for 44 ascorbate in incurable cancer. [Me dH ypotheses. 1991]
low-ascorbate patients and 246 days for 55 high-ascorbate patients. Three of the high-ascorbate patients were
Review Final report of the safety assessment of L-Ascorbic Acid, Calcium
still alive, their average survival being 1550 days, on April 1, 1980. Similar effectiveness of ascorbate was also
Ascorbate, Magnesium Ascorbate, Magnesium Ascorbyl Phosphate,[I nt JT oxicol. 2005]
Sodium
observed at the Kamioka Kozan Hospital. There were 31 patients with terminal cancer during the period
1975-1979. The average survival times were 48 days for 19 control patients and 115 days for 6 high-ascorbate Review Pharmacokinetics of vitamin C: insights into the oral and intravenous

patients. One of the high-ascorbate patients was still alive, his survival being 215 days. In addition to the administration of ascorbate. [P R Hea lth SciJ. 2008]
increase in survival times, the administration of large doses of ascorbate seemed to improve the quality of life.
» See Reviews... | » See All...
PMID: 6811475 [PubMed - indexed for MEDLINE]
Patient Drug Information

Ascorbic Acid (Cecon® Drops, Cenolate® , Cevi-Bid® , ...) Ascorbic acid is used
to prevent and treat scurvy, a disease caused by a lack of vitamin C in the body.

Source: AHFS Consumer Medication Information

Recent Activity

Turn Off Clear

Prolongation of survival times of terminal cancer patients by administration

of large dose...

Vitamin C and cancer: an overview.

The influence of ascorbic acid on the growth of solid tumors in mice and on
tumor control ...

Vitamin C lowers mutagenic and toxic effect of hexavalent chromium in

guinea pigs.

A case-control study of nutrient status and invasive cervical cancer. I.

Dietary indicator...

Display AbstractPlus Show 20 Sort By Send to

Write to the Help Desk
NCBI | NLM | NIH
Department of Health & Human Services
Privacy Statement | Freedom of Information Act | Disclaimer